A detailed history of Seizert Capital Partners, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Seizert Capital Partners, LLC holds 717,254 shares of BMY stock, worth $41.1 Million. This represents 1.72% of its overall portfolio holdings.

Number of Shares
717,254
Previous 607,405 18.08%
Holding current value
$41.1 Million
Previous $25.2 Million 47.14%
% of portfolio
1.72%
Previous 1.28%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$39.66 - $51.75 $4.36 Million - $5.68 Million
109,849 Added 18.08%
717,254 $37.1 Million
Q2 2024

Aug 07, 2024

SELL
$40.25 - $52.99 $1.43 Million - $1.88 Million
-35,528 Reduced 5.53%
607,405 $25.2 Million
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $6.79 Million - $7.7 Million
141,533 Added 28.23%
642,933 $34.9 Million
Q4 2023

Feb 07, 2024

SELL
$48.48 - $57.85 $926,064 - $1.11 Million
-19,102 Reduced 3.67%
501,400 $25.7 Million
Q3 2023

Nov 06, 2023

BUY
$57.89 - $64.73 $489,865 - $547,745
8,462 Added 1.65%
520,502 $30.2 Million
Q2 2023

Jul 27, 2023

BUY
$63.71 - $70.74 $4.99 Million - $5.54 Million
78,308 Added 18.05%
512,040 $32.7 Million
Q1 2023

May 09, 2023

BUY
$65.71 - $74.53 $2.26 Million - $2.57 Million
34,458 Added 8.63%
433,732 $30.1 Million
Q4 2022

Jan 30, 2023

SELL
$68.48 - $81.09 $1.62 Million - $1.92 Million
-23,688 Reduced 5.6%
399,274 $28.7 Million
Q3 2022

Nov 02, 2022

BUY
$0.13 - $76.84 $123 - $72,998
950 Added 0.23%
422,962 $30.1 Million
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $679,941 - $748,852
-9,363 Reduced 2.17%
422,012 $32.5 Million
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $286,742 - $343,830
-4,664 Reduced 1.07%
431,375 $31.5 Million
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $19.6 Million - $22.8 Million
364,645 Added 510.75%
436,039 $27.2 Million
Q3 2021

Nov 03, 2021

BUY
$59.17 - $69.31 $2.09 Million - $2.44 Million
35,240 Added 97.47%
71,394 $4.22 Million
Q2 2021

Aug 05, 2021

BUY
$61.91 - $67.42 $97,755 - $106,456
1,579 Added 4.57%
36,154 $2.42 Million
Q1 2021

May 05, 2021

SELL
$59.34 - $66.74 $802,751 - $902,858
-13,528 Reduced 28.12%
34,575 $2.18 Million
Q4 2020

Feb 08, 2021

BUY
$57.74 - $65.43 $85,628 - $97,032
1,483 Added 3.18%
48,103 $2.98 Million
Q3 2020

Nov 03, 2020

BUY
$57.43 - $63.64 $542,368 - $601,016
9,444 Added 25.4%
46,620 $2.81 Million
Q2 2020

Aug 06, 2020

BUY
$54.82 - $64.09 $1.12 Million - $1.31 Million
20,442 Added 122.16%
37,176 $2.19 Million
Q1 2020

May 05, 2020

SELL
$46.4 - $67.43 $638,092 - $927,297
-13,752 Reduced 45.11%
16,734 $933,000
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $1.2 Million - $1.56 Million
24,312 Added 393.78%
30,486 $1.96 Million
Q3 2019

Nov 07, 2019

BUY
$42.77 - $50.71 $4,490 - $5,324
105 Added 1.73%
6,174 $313,000
Q4 2018

Feb 08, 2019

BUY
$48.76 - $63.23 $10,922 - $14,163
224 Added 3.83%
6,069 $315,000
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $59,940 - $65,349
1,000 Added 20.64%
5,845 $358,000
Q3 2017

Oct 31, 2017

SELL
$55.23 - $63.74 $220,920 - $254,960
-4,000 Reduced 45.22%
4,845 $309,000
Q2 2017

Aug 09, 2017

BUY
N/A
8,845
8,845 $493,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Seizert Capital Partners, LLC Portfolio

Follow Seizert Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seizert Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Seizert Capital Partners, LLC with notifications on news.